AAV Vector PKP2 Gene Therapy for Arrhythmogenic Cardiomyopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac diseases, such as cardiomyopathy, particularly arrhythmogenic right ventricular cardiomyopathy (ARVC), are inadequate due to high mortality and morbidity rates, and existing therapies are not suitable for patients with advanced heart failure and co-morbid diseases, highlighting the need for more targeted approaches like gene therapy.
Innovation Solution
The method involves delivering a gene therapy vector encoding for the plakophilin-2 (PKP2) protein using a viral vector, specifically adeno-associated virus (AAV), to cardiomyocytes to correct haploinsufficiency and increase desmosomal expression, thereby treating or preventing cardiomyopathy by enhancing PKP2 protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacologic treatments are used for cardiomyopathy, then current standard of care is maintained, but mortality and morbidity remain unacceptably high
Solution Approach 1:
The patent changes the fundamental parameter of treatment from pharmacologic to gene therapy, delivering functional PKP2 gene sequences via viral vectors to correct the underlying genetic defect in cardiomyocytes, thereby resolving the contradiction between conventional treatment limitations and patient needs
Solution Approach 2:
The patent uses viral vectors to deliver copies of the functional PKP2 gene sequence to cardiomyocytes, replacing the defective endogenous gene expression and restoring normal desmosomal protein function, which addresses both mortality/morbidity reduction and patient suitability issues
2Reliability
If gene therapy is used to deliver therapeutic polynucleotide sequences to cardiomyocytes, then treatment efficacy is improved, but delivery specificity and safety must be maintained
Solution Approach 1:
The patent employs cardiac-specific promoters (such as TNNT2 promoter) in the gene therapy vector to ensure that PKP2 expression is localized specifically to cardiomyocytes, thereby achieving high treatment efficacy while minimizing harmful effects on other tissues through spatially restricted gene expression
Solution Approach 2:
The patent uses viral vectors as intermediary carriers to deliver the therapeutic PKP2 gene sequence to cardiomyocytes, with the viral vector serving as a controlled mediator that ensures specific cell targeting and safe delivery, thus resolving the contradiction between efficacy and safety
3Quantity of substance
If PKP2 expression is increased in haploinsufficient cardiomyocytes, then desmosomal expression is improved, but achieving sufficient expression levels requires precise control
Solution Approach 1:
The patent changes the expression parameter by using cardiac-specific promoters with regulated strength and controlling the dosage of viral vector delivery, thereby achieving precise control over PKP2 protein expression levels to reach therapeutic thresholds without excessive expression, resolving the contradiction between quantity and precision
Data Source
AI summary
Disclosed are a composition and method of treating or preventing cardiomyopathy in a human subject. In some embodiments, the method comprises delivering a therapeutic dose of a gene therapy vector to cardiomyocytes of the human subject, wherein the gene therapy vector comprises a nucleic acid sequence encoding for PKP2.